AstraZeneca's patent on asthma drug invalidated by U.S. court

February 16, 2015 12:46 AM

7 0

AstraZeneca's patent on asthma drug invalidated by U.S. court

NEW YORK (Reuters) - A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version.

Actavis Plc said that the U.S. District Court for the District of New Jersey ruling prompted it to release a generic version of the lung drug. Another generic version of Pulmicort Respules from Teva Pharmaceutical Industries, under a previous agreement with AstraZeneca, has been on the market for so...

Read more

To category page

Loading...